Pacira BioSciences' Share-based Compensation rose 565.38% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 963.27%. This contributed to the annual value of $51.2 million for FY2024, which is 684.0% up from last year.
Per Pacira BioSciences' latest filing, its Share-based Compensation stood at $14.0 million for Q3 2025, which was up 565.38% from $15.5 million recorded in Q2 2025.
Pacira BioSciences' Share-based Compensation's 5-year high stood at $15.5 million during Q2 2025, with a 5-year trough of $10.1 million in Q1 2021.
For the 5-year period, Pacira BioSciences' Share-based Compensation averaged around $12.3 million, with its median value being $12.4 million (2023).
As far as peak fluctuations go, Pacira BioSciences' Share-based Compensation crashed by 510.22% in 2023, and later skyrocketed by 2353.88% in 2025.
Over the past 5 years, Pacira BioSciences' Share-based Compensation (Quarter) stood at $10.9 million in 2021, then grew by 16.41% to $12.7 million in 2022, then fell by 2.03% to $12.4 million in 2023, then fell by 1.24% to $12.3 million in 2024, then increased by 13.96% to $14.0 million in 2025.
Its Share-based Compensation was $14.0 million in Q3 2025, compared to $15.5 million in Q2 2025 and $14.6 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value